Potentiation of cardiac electrophysiologic effects of verapamil after autonomic blockade or cardiac transplantation. 1987

A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt

Cardiac electrophysiologic effects of verapamil in vivo are the result of both direct and indirect actions on the heart (the latter due to augmentation of sympathetic neural tone, diminution of parasympathetic neural tone, and increased circulating catecholamines). In this study we assessed the interaction of verapamil's direct and indirect actions on electrophysiologic properties of the heart in awake, previously instrumented, unsedated dogs. After administration of intravenous verapamil (0.2 mg/kg), electrophysiologic effects were assessed serially over a 1 hr period in 10 awake dogs before (group 1 studies) and during pharmacologic autonomic blockade (group 2 studies), and in a subset of these dogs (n = 5) after orthotopic cardiac transplantation (group 3 studies). In group 1 dogs, sinus cycle length (SCL) initially shortened after verapamil (postverapamil 379 +/- 50 msec vs baseline of 494 +/- 72 msec, p less than .001) and subsequently gradually prolonged. In groups 2 and 3, transient SCL shortening was absent. SCL prolonged promptly after verapamil, and sinus arrest developed in two of 10 group 2 and two of five group 3 animals. Verapamil exerted a negative dromotropic effect on atrioventricular node conduction in all three experimental groups, as assessed by drug-induced changes in minimum cycle length with sustained 1:1 atrioventricular conduction and measurements of atrioventricular node effective and functional refractory period. However, compared with findings in group 1, this negative dromotropic effect occurred more rapidly and was markedly potentiated in groups 2 and 3.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D012032 Refractory Period, Electrophysiological The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state. Period, Neurologic Refractory,Periods, Neurologic Refractory,Refractory Period, Neurologic,Tetanic Fade,Vvedenskii Inhibition,Wedensky Inhibition,Inhibition, Vvedenskii,Inhibition, Wedensky,Neurologic Refractory Period,Neurologic Refractory Periods,Neuromuscular Fade,Neuromuscular Transmission Fade,Refractory Period, Neurological,Refractory Periods, Neurologic,Electrophysiological Refractory Period,Electrophysiological Refractory Periods,Fade, Neuromuscular,Fade, Neuromuscular Transmission,Fade, Tetanic,Neurological Refractory Period,Neurological Refractory Periods,Refractory Periods, Electrophysiological,Refractory Periods, Neurological,Transmission Fade, Neuromuscular
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001283 Atrioventricular Node A small nodular mass of specialized muscle fibers located in the interatrial septum near the opening of the coronary sinus. It gives rise to the atrioventricular bundle of the conduction system of the heart. AV Node,A-V Node,Atrio-Ventricular Node,A V Node,A-V Nodes,AV Nodes,Atrio Ventricular Node,Atrio-Ventricular Nodes,Atrioventricular Nodes,Node, A-V,Node, AV,Node, Atrio-Ventricular,Node, Atrioventricular,Nodes, A-V,Nodes, AV,Nodes, Atrio-Ventricular,Nodes, Atrioventricular
D001285 Atropine An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine. AtroPen,Atropin Augenöl,Atropine Sulfate,Atropine Sulfate Anhydrous,Atropinol,Anhydrous, Atropine Sulfate,Augenöl, Atropin,Sulfate Anhydrous, Atropine,Sulfate, Atropine
D001340 Autonomic Nerve Block Interruption of sympathetic pathways, by local injection of an anesthetic agent, at any of four levels: peripheral nerve block, sympathetic ganglion block, extradural block, and subarachnoid block. Sympathetic Nerve Block,Autonomic Nerve Blocks,Block, Autonomic Nerve,Block, Sympathetic Nerve,Blocks, Autonomic Nerve,Blocks, Sympathetic Nerve,Nerve Block, Autonomic,Nerve Block, Sympathetic,Nerve Blocks, Autonomic,Nerve Blocks, Sympathetic,Sympathetic Nerve Blocks
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
September 1989, Journal of cardiovascular pharmacology,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
April 1984, Anesthesiology,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
May 1974, The Journal of pharmacology and experimental therapeutics,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
June 1984, Circulation,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
November 1979, Japanese heart journal,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
April 1981, Circulation,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
May 1980, The Journal of pharmacology and experimental therapeutics,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
December 1967, Bulletin of the New York Academy of Medicine,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
May 1992, Chest,
A Z Qi, and I C Tuna, and C C Gornick, and T P Barragry, and J W Blatchford, and W S Ring, and R M Bolman, and M J Walker, and D G Benditt
April 1991, Clinical cardiology,
Copied contents to your clipboard!